PEP51™

Using Intracellular Peptides for Brain Health

PEP51, a 4 amino-acid peptide, works through natural brain signaling pathways to protect brain health, showing strong activity in preclinical seizure models, with early research suggesting potential benefits for diseases linked to brain inflammation.

About

PEP51™

PEP51specifically targets cannabinoid-related pathways involved in neuro-inflammation and neuronal signaling, representing a new, largely unexplored, therapeutic opportunity.

PEP51 specifically targets cannabinoid-related pathways involved in neuroinflammation and neuronal signaling, representing a new, largely unexplored, therapeutic opportunity.

PEP 51 is a proprietary peptide derived from Hemopressin (a peptide generated during the normal recycling of proteins through the cell’s ubiquitin-proteasome system). While these molecules were believed for decades to be simple byproducts of protein degradation, growing evidence shows that many act as powerful regulators of cellular signaling.

How it works

Mechanistic studies indicate that PEP 51 interacts strongly with cannabinoid receptors. These receptors play a central role in regulating immune and inflammatory responses in the nervous system and peripheral tissues, as well as induces neuronal growth. By interacting with this signaling network, PEP 51 supports the reduction of key inflammatory cytokines. This specific interaction with the endocannabinoid system helps explain the peptide’s dual neuro-supportive and anti-inflammatory effects.

No data was found

Potential Applications

Brain Health

Challenge: Developing next-generation treatments for a variety of neurological and neurodegenerative disorders requires molecules that can cross biological barriers and interact with complex signaling networks.

Solution: PEP 51 utilizes the cell's own molecular language to target disease pathways through neuro supportive potential and anti-inflammatory properties.

Findings: By combining cannabinoid-modulating properties with strong neurological function, PEP 51 is positioned as a candidate for the development of new therapies targeting brain health.

MRI or magnetic resonance imaging of the head and brain. Close u

Epilepsy

Challenge: There is a critical need for highly effective oral therapeutic candidates that can significantly delay or prevent the onset of seizures.

Solution: Researchers evaluated the effects of orally administered NFKF, the peptide fragment that forms the basis of Pep51, in a mouse model of pilocarpine-induced epilepsy.

Findings: Preclinical studies demonstrated that NFKF delayed the onset of seizures with approximately 100-fold greater potency than cannabidiol.

Caucasian Female Doctor Analyzing Brain and Spine Mri Scans on Computer Monitor

Multiple Sclerosis

Challenge: Neuroinflammatory diseases often result in poor neurological scores and impaired locomotor function, requiring innovative treatments where current options remain limited. Solution: PEP 51 was administered orally

Findings: Mice treated with PEP 51 showed significantly improved neurological scores and better locomotor activity compared with control or untreated animals.

Scientific Publications:

Pep51: Harnessing Intracellular Peptides for Brain Health

Journal: Journal

Year: Year

View Publication

Frequently Asked Questions

Scientific answers to common questions about us and our health platform

PEP51is a proprietary intracellular peptide that works to protect brain health, showing strong anti-seizure activity, with early research suggesting potential benefits for diseases linked to brain inflammation.

PEP51interacts with natural brain signaling pathways, specifically targeting cannabinoid receptors, which regulate immune and inflammatory responses in the nervous system and peripheral tissues.

PEP51represents a new, largely unexplored therapeutic opportunity for conditions involving neuro-inflammation and neuronal signaling

PEP51specifically targets cannabinoid-related pathways involved in neuro-inflammation and neuronal signaling, unlike many other peptides previously considered simple byproducts of protein degradation.

PEP51is derived from Hemopressin, a fragment of hemoglobin, a peptide generated during the normal recycling of proteins through the cell’s ubiquitin-proteasome system.

Partner with Us

Join us to revolutionize the use of bioactive peptides to better lives worldwide. Our biotechnology advances peptide therapeutics through focused discovery, grounded in deep peptide expertise.

Our partners across pharma, food, biology, and beyond help drive the global market impact of novel peptide therapeutics.

Contact us

First Name

Last Name

Corporate Email

Company Name

Phone Number

Job Title

Topic of inquiry

How can we collaborate?

POLICY

I agree to the Privacy Policy

Enroll me on your mailing list for newsletters and updates

Get in touch

Headquarters

Proteimax Israel (HQ)
Proteimax Americas (US Office)
Proteimax Brazil (R&D Center)

Email

info@proteimax.com

This contact channel is reserved for potential corporate partnerships only. If you are a consumer with questions about PEP19, please reach out to your local territory distributor.

For USA inquiries, please contact